Please assess the completion status of the following clinical trial:

Trial Title: Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with high risk hematological malignancies, including those with induction failure and after treated or untreated relapse. High risk hematological malignancies include: Acute myelogenous or lymphocytic leukemia with induction failure of after relapse, myelodysplastic syndrome of intermediate and high risk according to Greenberg criteria, chronic myelogenous leukemia in accelerated phase or blast crisis, non-Hodgkin's and Hodgkin's lymphoma with induction failure or relapse after chemotherapy and refractory or relapsed chronic lymphocytic leukemia.~2. HLA-identical sibling or matched unrelated donor transplants not eligible for protocols of higher priority.~3. Age 18-75 years.~4. Bilirubin \</=1.5 mg/dl, serum glutamic-pyruvic transaminase (SGPT) \</= 200 IU/ml.~5. Creatinine \</=1.6 mg/dl.~Exclusion Criteria:~1. Regimens including rituximab or alemtuzumab in the preparative regimen.~2. Patients can not have received prior treatment with gemtuzumab.~3. Planned conditioning chemotherapy for transplant can not include gemtuzumab.~4. Planned conditioning chemotherapy for transplant can not include the busulfan and cyclophosphamide regimen.~5. HIV seropositivity~6. Uncontrolled infection, not responding to adequate antimicrobial therapy after 7 days of treatment. The protocol PI is the final arbiter of eligibility.~7. Pregnancy~8. Inability to sign consent.~9. Patients who are past recipients of allogeneic or autologous stem cell transplants from any source.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Thymoglobulin + Sirolimus + MMF (Type: EXPERIMENTAL): Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.

Based on this trial design, predict the completion outcome and termination type (if applicable).